- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05556200
A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Jieqiong Liu, MD,PhD
- Phone Number: 020-34071156
- Email: liujieqiong01@163.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510120
- Recruiting
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
-
Contact:
- Jieqiong Liu, M.D., Ph.D.
-
Shanwei, Guangdong, China, 516600
- Recruiting
- Shenshan Medical Center, Memorial Hospital of Sun Yat-sen University
-
Contact:
- Yandan Yao, M.D., Ph.D.
- Email: yaoyand@mail.sysu.edu.cn
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Recruiting
- The First Affiliated Hospital of Nanjing Medical University
-
Contact:
- Wenbin Zhou, M.D., Ph.D.
- Email: zhouwenbin@njmu.edu.cn
-
-
Shanghai
-
Shanghai, Shanghai, China, 200433
- Recruiting
- Second Military Medical University
-
Contact:
- Hengyu Li, M.D., Ph.D.
- Email: lhy@smmu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients sign the written informed consent.
- Women aged 18-70.
- Patients with histologically confirmed operable invasive breast cancer (T1cN1-2 or T2-4N0-2)[ER-negative(IHC<1%), PR-negative(IHC<1%), HER2-negative(IHC-/+ or IHC++ and FISH/CISH-)].
- Percentage of tumor-infiltrating lymphocytes >10% in baseline breast tumor.
- Patients with at least one measuring lesion that was conformed to RECIST v1.1 standard.
- No previous breast cancer-related treatment, including chemotherapy, immunotherapy, endocrine therapy, radical surgery, or radiotherapy.
- Patients can swallow pills.
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.
- Patients with a life expectancy of at least 12 weeks.
The patient's blood test results prior to enrollment met the following criteria: • Hb≥90g/L; • Plt≥100^9/L; • Serum albumin ≥3g/dL; • Neutrophils≥1.5^9/L;
• TSH≤ normal upper limit (ULN);
- ALT and AST ≤1.5 ULN (liver metastases ≤3 ULN);
- TBIL ≤ULN (total bilirubin ≤1.5 ULN in Gilbert's syndrome or liver metastasis subjects);
- ALT and AST ≤1.5 ULN (liver metastases ≤3 ULN);
- AKP≤ 2.5 ULN;
- Renal function within 7 days before the first administration: serum creatinine ≤1.5 ULN or creatinine clearance ≥60mL/min.
- Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose and must be willing to use very efficient barrier methods of contraception for the course of the study through 6 months after the last dose of study treatment.
Exclusion Criteria:
- Combination of other malignancies or previous malignancies other than breast cancer within the last 5 years, except for basal cell carcinoma or flat cell carcinoma of the skin or carcinoma in situ of the uterine cervix that has been adequately controlled by treatment.
- Those who are not suitable for immunotherapy in combination with active infection.
- The combination of severe non-malignant disease that would affect patient compliance or put the patient at risk.
- Concomitant with other antineoplastic therapy or are participating in other clinical trials.
- Male breast cancer, bilateral breast cancer or inflammatory breast cancer.
- Patients with dementia, mental abnormality or any mental illness that prevents understanding of the informed consent form.
- Patients with history of allergic reaction or contraindication to the use of any drug component of this trial.
- Patients with any active autoimmune disease or a history of autoimmune disease (e.g., the following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enterocolitis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, hypothyroidism; subjects with vitiligo or whose asthma has completely resolved in childhood and does not require any intervention in adulthood may be included; (Patients with asthma that requires medical intervention with bronchodilators cannot be included).
- Have cardiac clinical symptoms or disease that are not well controlled, such as:
(1) NYHA class 2 or higher heart failure; (2) Unstable angina pectoris; (3) Myocardial infarction within 1 year; (4) clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention.
10. Urine routine suggestive of urine protein ≥++, or confirmed 24-hour urine protein amount ≥1.0g.
11. Known presence of hereditary or acquired bleeding and thrombotic tendencies (e.g., hemophiliacs, coagulation disorders, thrombocytopenia, hypersplenism, etc.).
12. Patients with congenital or acquired immune deficiencies (e.g., HIV-infected individuals).
13. Live vaccines administered less than 4 weeks prior to study drug administration or possibly during the study.
14. Active tuberculosis. 15. Patients have received oral or intravenous antibiotic therapy within 2 weeks prior to neoadjuvant therapy.
16. Major surgical procedure within 4 weeks prior to the start of study treatment or anticipated need for major surgical procedure during the course of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experiment
Eligible patients enrolled receive camrelizumab 200 mg, iv, d1, every 21 days (3 mg/kg if weight <50 kg) in combination with apatinib 250 mg, po, qd for neoadjuvant treatment for 8 cycles. Patients evaluated after neoadjuvant therapy with pCR receive 9 cycles of postoperative adjuvant camrelizumab (200 mg, iv, or 3 mg/kg if weight <50 kg, d1,q3W) + apatinib (250 mg, po, qd). Patients with non-pCR after neoadjuvant therapy receive adjuvant chemotherapy of the physician's choice (TPC). |
Camrelizumab 200 mg, iv, d1, q3W (3 mg/kg if weight <50 kg)
Other Names:
Apatinib 250 mg, po, qd
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathological Complete Remission (pCR) rate
Time Frame: After neoadjuvant study treatment and surgery, up to approximately 24-26 weeks
|
pCR rate (ypT0/Tis ypN0) is defined as the percentage of participants without residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy by current American Joint Committee on Cancer (AJCC) staging criteria assessed by the local pathologist at the time of definitive surgery.
|
After neoadjuvant study treatment and surgery, up to approximately 24-26 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: After neoadjuvant study treatment and surgery, up to approximately 24-26 weeks
|
The propotion of subjects with CR or PR according to RECIST v1.1.
|
After neoadjuvant study treatment and surgery, up to approximately 24-26 weeks
|
Breast Conservation Rate
Time Frame: Up to approximately 24-26 weeks
|
The percentage of patients who undergo breast-conserving surgery after neo-adjuvant therapy.
|
Up to approximately 24-26 weeks
|
Incidence of Treatment-Emergent Adverse Events
Time Frame: From the first drug administration to within 90 days for the last dose
|
Adverse events/serious adverse events.
|
From the first drug administration to within 90 days for the last dose
|
Event-Free Survival (EFS)
Time Frame: Up to approximately 8 years
|
Event-free survival (EFS) defined as the time from recruitment until documented disease recurrence, progression, or death from any cause in all participants.
EFS events covered under "disease recurrence" will include local, regional, or distant recurrence and contralateral breast cancer.
Ipsilateral or contralateral in situ disease and second primary non-breast cancers will not be counted as EFS events.
|
Up to approximately 8 years
|
Overall Survival (OS)
Time Frame: Up to approximately 8 years
|
defined as the time from randomization to death due to any cause.
|
Up to approximately 8 years
|
Frequencies of Biomarkers
Time Frame: Up to approximately 24-26 weeks
|
Biomarkers (including tumor/stromal PD-L1, stromal PD-1, tumor-infiltrating lymphocytes and tumor-infiltrating B cells, eg).
|
Up to approximately 24-26 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jieqiong Liu, M.D., Ph.D., Sun Yet-sen Memorial Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Triple Negative Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunologic Factors
- Protein Kinase Inhibitors
- Antibodies
- Antibodies, Monoclonal
- Apatinib
Other Study ID Numbers
- NeoCAT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Anti-PD-1 monoclonal antibody
-
Henlix, IncUnknown
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedSolid TumorUnited States
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingUterine Cervical CancerChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingLymphoma | Cervical Cancer | Malignant Mesothelioma | Advanced Solid Tumours | Non-Small-Cell Lung CancerChina
-
The First Affiliated Hospital with Nanjing Medical...Recruiting
-
Guangzhou Gloria Biosciences Co., Ltd.CompletedAdvanced Solid TumorsChina
-
Genor Biopharma Co., Ltd.RecruitingAlveolar Soft Part SarcomaChina
-
Shanghai Henlius BiotechRecruiting
-
Genor Biopharma Co., Ltd.RecruitingPeripheral T Cell LymphomaChina
-
RenJi HospitalCompletedNeoadjuvant Immunotherapy of Cisplatin-ineligible High Risk Upper Urinary Tract Urothelial CarcinomaChina